These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31755287)

  • 1. A new strategy for the treatment of atherothrombosis - inhibition of inflammation.
    Slíva J; Charalambous C; Bultas J; Karetová D
    Physiol Res; 2019 Nov; 68(Suppl 1):S17-S30. PubMed ID: 31755287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Thuren T; Zalewski A; Libby P
    Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical roles of inflammation in atherosclerosis.
    Moriya J
    J Cardiol; 2019 Jan; 73(1):22-27. PubMed ID: 29907363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation.
    Martínez GJ; Celermajer DS; Patel S
    Atherosclerosis; 2018 Feb; 269():262-271. PubMed ID: 29352570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
    Ridker PM
    Trans Am Clin Climatol Assoc; 2013; 124():174-90. PubMed ID: 23874021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis, and Atherogenesis.
    Westerterp M; Fotakis P; Ouimet M; Bochem AE; Zhang H; Molusky MM; Wang W; Abramowicz S; la Bastide-van Gemert S; Wang N; Welch CL; Reilly MP; Stroes ES; Moore KJ; Tall AR
    Circulation; 2018 Aug; 138(9):898-912. PubMed ID: 29588315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammation and cardiovascular diseases: lessons from seminal clinical trials.
    Liberale L; Montecucco F; Schwarz L; Lüscher TF; Camici GG
    Cardiovasc Res; 2021 Jan; 117(2):411-422. PubMed ID: 32666079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial.
    Everett BM; MacFadyen JG; Thuren T; Libby P; Glynn RJ; Ridker PM
    J Am Coll Cardiol; 2020 Oct; 76(14):1660-1670. PubMed ID: 33004131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atherothrombosis Prevention and Treatment with Anti-interleukin-1 Agents.
    Biondi-Zoccai G; Garmendia CM; Abbate A; Giordano A; Frati G; Sciarretta S; Antonazzo B; Versaci F
    Curr Atheroscler Rep; 2020 Jan; 22(1):4. PubMed ID: 31932973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atherosclerosis: perspectives of anti-inflammatory therapy.
    Nasonov EL; Popkova TV
    Ter Arkh; 2018 May; 90(5):4-12. PubMed ID: 30701884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis.
    Ridker PM
    Circ Res; 2019 Feb; 124(3):437-450. PubMed ID: 30702995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melatonin Ameliorates the Progression of Atherosclerosis via Mitophagy Activation and NLRP3 Inflammasome Inhibition.
    Ma S; Chen J; Feng J; Zhang R; Fan M; Han D; Li X; Li C; Ren J; Wang Y; Cao F
    Oxid Med Cell Longev; 2018; 2018():9286458. PubMed ID: 30254716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Antiatherosclerotic Therapies.
    Libby P; Everett BM
    Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):538-545. PubMed ID: 30816799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week.
    Ridker PM
    J Am Coll Cardiol; 2018 Dec; 72(25):3320-3331. PubMed ID: 30415883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammation in atherosclerotic cardiovascular disease.
    Shah PK; Lecis D
    F1000Res; 2019; 8():. PubMed ID: 31448091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease.
    Ridker PM; Rane M
    Circ Res; 2021 May; 128(11):1728-1746. PubMed ID: 33998272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-inflammatory therapy for atherosclerosis: interpreting divergent results from the CANTOS and CIRT clinical trials.
    Ridker PM
    J Intern Med; 2019 May; 285(5):503-509. PubMed ID: 30472762
    [No Abstract]   [Full Text] [Related]  

  • 18. High-density lipoprotein reduces inflammation from cholesterol crystals by inhibiting inflammasome activation.
    Thacker SG; Zarzour A; Chen Y; Alcicek MS; Freeman LA; Sviridov DO; Demosky SJ; Remaley AT
    Immunology; 2016 Nov; 149(3):306-319. PubMed ID: 27329564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease.
    Roman YM; Hernandez AV; White CM
    Ann Pharmacother; 2020 Oct; 54(10):1021-1029. PubMed ID: 32425120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Libby P; MacFadyen JG; Thuren T; Ballantyne C; Fonseca F; Koenig W; Shimokawa H; Everett BM; Glynn RJ
    Eur Heart J; 2018 Oct; 39(38):3499-3507. PubMed ID: 30165610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.